Video

Dr. D’Angelo on the Incidence and Prognosis of Merkel Cell Carcinoma

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the incidence and prognosis of patients with Merkel cell carcinoma (MCC).

MCC is a rare cancer that affects approximately 1,000 to 2,000 individuals in the United States each year, says D’Angelo. However, like many skin malignancies, the incidence of MCC is rising, D’Angelo explains.

Surgical excision of the tumor remains the standard of care for patients who present with localized MCC, D’Angelo says. Although this is an appropriate course of treatment, a proportion of patients will have disease recurrence and metastasis, D’Angelo explains. Notably, significant research advances have been made in the metastatic setting in recent years for this patient population, concludes D’Angelo.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center